Pulse Biosciences Announces Commercial and Clinical Partnership with Clayman Thyroid Center

Pulse Biosciences, Inc. (Nasdaq: PLSE) announced on October 14, 2026, that it has entered into a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The agreement covers two primary areas: the commercial use of the nPulse Vybrance Percutaneous Electrode System at the center and a clinical collaboration to generate additional data on the technology's use in treating benign thyroid nodules.

Under the commercial component, the Clayman Thyroid Center is now treating patients with the Vybrance System as part of a controlled market development strategy. The center is described as the only site in the Tampa Bay Area offering nPulse technology for symptomatic benign thyroid nodules. The clinical partnership involves Pulse Biosciences and the Clayman Thyroid Center collaborating on the collection of real-world outcomes from patients treated at the center, as well as on formal clinical studies evaluating nsPFA energy for the treatment of benign thyroid nodules.

Pulse Biosciences expects this work to add meaningfully to the body of evidence supporting the Vybrance System. The company’s CEO, Paul LaViolette, stated that the Clayman Thyroid Center is one of the largest thyroid surgery centers across the country with significant referral patterns, and that the partnership allows for the expansion of access to nPulse Vybrance technology for patients treated in a high-volume center.

The nPulse Vybrance Percutaneous Electrode System delivers ultra-short bursts of electrical energy to cells in a precise, nonthermal procedure under ultrasound guidance. Unlike treatments that rely on heat, nsPFA energy is designed to clear ablated cells while sparing adjacent acellular tissue to preserve nearby critical structures such as nerves and vessels. Patients undergoing therapy with the Vybrance System are able to go home the same day, avoid surgical risks and scarring, and typically experience relief from symptoms commencing only a few weeks following the minimally invasive procedure.